AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-CKD Trial for Patients With and Without Type-2 Diabetes

 AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-CKD Trial for Patients With and Without Type-2 Diabetes

AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-CKD Trial for CKD Patients With and Without Type-2 Diabetes

Shots:

  • The P-III DAPA-CKD trial involves assessing of Farxiga (10mg) + SOC vs PBO in 4.304 patients with CKD stages 2-4 and elevated urinary albumin excretion, with/ out T2D 
  • Results: 39% reduction in worsening of renal function or risk of CV or renal death, ARR (5.3%) @2.4yrs., met its 2EPs with 31% reduction in death, safety and tolerability were consistent, AEs (29.5% vs 33.9%)
  • Farxiga (PO, qd) is an SGLT2 inhibitor indicated in adults for the treatment of insufficiently controlled T2D as both monothx. and combination therapy as an adjunct to diet and exercise to improve glycemic control, weight loss and BP reduction

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: FX Empire

Related News: AstraZeneca Report Results of Farxiga in P-III DAPA-CKD Study for Patients with Chronic Kidney Disease

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post